Barclays
ORIC icon

Barclays’s Oric Pharmaceuticals ORIC Stock Holding History

Barclays’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$157K Sell
12,429
-706,106
-98% -$8.02M ﹤0.01% 3828
2025
Q4 		$5.88M Buy
718,535
+534,444
+290% +$6.15M ﹤0.01% 2092
2025
Q3 		$2.21M Buy
184,091
+41,410
+29% +$436K ﹤0.01% 2816
2025
Q2 		$1.45M Buy
142,681
+40,891
+40% +$275K ﹤0.01% 3090
2025
Q1 		$568K Sell
101,790
-12,902
-11% -$113K ﹤0.01% 3447
2024
Q4 		$926K Buy
114,692
+7,431
+7% +$68.2K ﹤0.01% 3424
2024
Q3 		$1.1M Buy
107,261
+56,474
+111% +$558K ﹤0.01% 3297
2024
Q2 		$359K Buy
50,787
+17,633
+53% +$158K ﹤0.01% 3241
2024
Q1 		$456K Sell
33,154
-21,045
-39% -$250K ﹤0.01% 3650
2023
Q4 		$499K Buy
54,199
+46,484
+603% +$336K ﹤0.01% 3875
2023
Q3 		$46.7K Sell
7,715
-57
-0.7% -$467 ﹤0.01% 3901
2023
Q2 		$60.3K Buy
+7,772
New +$44.1K ﹤0.01% 3756
2022
Q2 		– Sell
-5,252
Closed -$29K – 5195
2022
Q1 		$29K Buy
+5,252
New +$47.3K ﹤0.01% 4313

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Barclays's ORIC Position: Q1 2026 in Review

Barclays reduced its Oric Pharmaceuticals (ORIC) stake by 98% in Q1 2026, selling an estimated $8.02M and leaving 12,429 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #3828.

Barclays first reported a position in ORIC in Q1 2022 and has held it in 13 quarters since. The position peaked at $5.88M in Q4 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Barclays held 12,429 shares of Oric Pharmaceuticals worth $157K as of Q1 2026.
  • Barclays sold 706,106 Oric Pharmaceuticals shares in Q1 2026, an estimated $8.02M.
  • Oric Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3828 holding.
  • Barclays first reported a position in Oric Pharmaceuticals in Q1 2022 and has held it in 13 quarters since.
  • Barclays's Oric Pharmaceuticals position peaked at $5.88M in Q4 2025.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.